home / open_comments

documents

Federal regulatory documents currently open for public comment. ⚠ Derive comment deadlines from comment_end_datetime converted to America/New_York, never from comment_end_date, which is mid-correction and may be one day late (DataDawn queue #498).

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

perpetual_docket
1 = a standing/perpetual docket carrying a sentinel comment-end date (2050 or later; in practice 2099/2100 — agency guidance and exemption dockets that never close). 0 = an ordinary docket with a real deadline. NULL = no end date reported. The site's Open-for-Comment surface EXCLUDES perpetual_docket = 1 by default, so the site count and the bulk dump answer the same question differently: the dump is complete and includes them.
comment_end_date
The comment deadline as an Eastern (America/New_York) calendar date — CORRECTED in the 2026-09-06 daily snapshot (DataDawn queue #498): a snapshot whose _metadata row comment_end_date_grain reads 'eastern' carries the Eastern date; the pre-correction snapshots (through 2026-09-05) held the UTC-rolled day, one day LATE on every end-of-day close. Federal comment periods close at 11:59:59 PM Eastern and the source publishes that instant in UTC ('2026-08-26T03:59:59Z' = the 2026-08-25 deadline). Prefer comment_end_datetime for any arithmetic and convert it to America/New_York yourself; never 'subtract a day' from this column.
comment_end_datetime
AUTHORITATIVE. The full UTC instant of the comment deadline ('2026-08-26 03:59:59' == 11:59:59 PM Eastern on 2026-08-25). Convert to America/New_York for the official date; prefer this column over comment_end_date for anything computed.

143 rows where agency_id = "FDA" sorted by comment_end_datetime descending

✎ View and edit SQL

This data as json, CSV (advanced)

document_type 4

  • Other 70
  • Notice 66
  • Proposed Rule 5
  • Rule 2

agency_id 1

  • FDA · 143 ✖
id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date comment_end_datetime ▲ perpetual_docket last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2015-N-3469-0001 FDA FDA-2015-N-3469 Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket Notice Notice of Availability 2015-10-27 2015 10 2015-10-27 2050-02-21 2050-02-22 04:59:59 1 2026-08-11 09:00:50 2015-27270 1 0 0900006481cf17b1
FDA-2015-N-3534-0001 FDA FDA-2015-N-3534 Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket Notice Notice of Availability 2015-10-27 2015 10 2015-10-27 2050-02-21 2050-02-22 04:59:59 1 2026-09-20 09:00:16 2015-27271 1 0 0900006481cf1710
FDA-2011-N-0655-0041 FDA FDA-2011-N-0655 Animal Generic Drug User Fee Act; Public Meeting; Request for Comments Notice Request for Comments 2026-04-17 2026 4 2026-04-17 2027-12-01 2027-12-02 04:59:59 0 2026-07-01 09:00:24 2026-07497 1 0 09000064b928930a
FDA-2011-N-0656-1315 FDA FDA-2011-N-0656 Animal Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate Notice General Notice 2026-05-11 2026 5 2026-05-11 2027-12-01 2027-12-02 04:59:59 0 2026-08-13 14:40:33 2026-09283 1 0 09000064b92cacd0
FDA-2011-N-0655-0042 FDA FDA-2011-N-0655 Animal Generic Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Generic Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate Notice Notice of Intent 2026-05-11 2026 5 2026-05-11 2027-12-01 2027-12-02 04:59:59 0 2026-08-13 14:41:39 2026-09284 1 0 09000064b92cf91b
FDA-2011-N-0656-1314 FDA FDA-2011-N-0656 Animal Drug User Fee Act; Public Meeting; Request for Comments Notice Request for Comments 2026-04-17 2026 4 2026-04-17 2027-12-01 2027-12-02 04:59:59 0 2026-08-20 09:01:12 2026-07498 1 0 09000064b928948d
FDA-2026-N-7864-0001 FDA FDA-2026-N-7864 Data Request (DR001): Use of the pH Cycling Test Model as a Testing Procedure for Fluoride Dentifrice Drug Products in Over-the-Counter (OTC) Monograph M021: Anticaries Drug Products for Over-the-Counter Human Use Other Request 2026-07-28 2026 7 2026-07-28 2027-01-25 2027-01-26 04:59:59 0 2026-07-28 16:50:16   1 0 09000064b93c7444
FDA-2026-N-0131-0001 FDA FDA-2026-N-0131 FDA Rare Disease Innovation Hub Future Programming; Request for Comments Notice Request for Comments 2026-01-30 2026 1 2026-01-30 2026-12-31 2027-01-01 04:59:59 0 2026-07-08 09:00:11 2026-01903 1 0 09000064b91893ee
FDA-2025-N-3262-0001 FDA FDA-2025-N-3262 Substances Generally Recognized as Safe Proposed Rule Notice of Proposed Rulemaking (NPRM) 2026-08-11 2026 8 2026-08-11 2026-12-09 2026-12-10 04:59:59 0 2026-10-08 09:00:31 2026-16296 1 0 09000064b942ea41
FDA-2026-N-5347-0001 FDA FDA-2026-N-5347 Nonclinical Testing Terminology Proposed Rule Notice of Proposed Rulemaking (NPRM) 2026-09-22 2026 9 2026-09-22 2026-12-07 2026-12-08 04:59:59 0 2026-10-08 09:00:48 2026-19349 1 0 09000064b95ae769
FDA-2026-N-5347-0002 FDA FDA-2026-N-5347 Nonclinical Testing Terminology Rule Direct Final Rule 2026-09-22 2026 9 2026-09-22 2026-12-07 2026-12-08 04:59:59 0 2026-10-08 09:00:48 2026-19350 1 0 09000064b95ae59d
FDA-2026-D-8693-0002 FDA FDA-2026-D-8693 Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Guidance for Industry; Draft Guidance for Industry Other Guidance 2026-09-02 2026 9 2026-09-02 2026-12-01 2026-12-02 04:59:59 0 2026-09-03 00:56:30   1 0 09000064b94bc729
FDA-2026-D-8693-0001 FDA FDA-2026-D-8693 Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Draft Guidance for Industry; Availability Notice Notice of Availability 2026-09-02 2026 9 2026-09-02 2026-12-01 2026-12-02 04:59:59 0 2026-09-03 18:40:25 2026-17961 1 0 09000064b94bf507
FDA-2026-N-10132-0001 FDA FDA-2026-N-10132 Agency Information Collection Activities; Proposed Collection; Comment Request; Protection of Human Subjects and Institutional Review Boards Notice 60 Day Proposed Information Collection 2026-09-29 2026 9 2026-09-29 2026-11-30 2026-12-01 04:59:59 0 2026-09-29 17:15:35 2026-19849 1 0 09000064b95e7083
FDA-2012-N-1021-0107 FDA FDA-2012-N-1021 Instructions for Submitting Comments on the CDRH Fiscal Year 2027 Proposed Guidance Development Other Additional Information 2026-10-01 2026 10 2026-10-01 2026-11-30 2026-12-01 04:59:59 0 2026-10-07 09:00:30   1 0 09000064b95fb842
FDA-2018-D-4533-2363 FDA FDA-2018-D-4533 Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request Notice Notice of Availability 2026-08-28 2026 8 2026-08-28 2026-11-27 2026-11-28 04:59:59 0 2026-08-28 16:31:49 2026-17580 1 0 09000064b94a6448
FDA-2018-D-4533-2364 FDA FDA-2018-D-4533 Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities; Draft Guidance Other Guidance 2026-08-28 2026 8 2026-08-28 2026-11-27 2026-11-28 04:59:59 0 2026-10-06 09:00:30   1 0 09000064b94a6e26
FDA-2015-N-3326-0056 FDA FDA-2015-N-3326 Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments Notice Request for Comments 2026-09-25 2026 9 2026-09-25 2026-11-25 2026-11-26 04:59:59 0 2026-10-06 09:00:35 2026-19660 1 0 09000064b95c53b7
FDA-2026-N-9505-0001 FDA FDA-2026-N-9505 Robotically-Assisted Surgical Devices—Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability Notice Notice of Availability 2026-09-25 2026 9 2026-09-25 2026-11-24 2026-11-25 04:59:59 0 2026-09-25 19:21:13 2026-19704 1 0 09000064b95c549b
FDA-2026-P-5995-0001 FDA FDA-2026-P-5995 Suitability Petition from Hyman, Phelps, & McNamara P.C. Other Petition(s) 2026-05-28 2026 5 2026-05-28 2026-11-24 2026-11-25 04:59:59 0 2026-09-29 15:44:43   1 0 09000064b92f59e1
FDA-2026-N-8563-0001 FDA FDA-2026-N-8563 Regulatory Science Innovations Catalyzing Medical Device Development_Co-sponsored Public Meeting Other Meeting 2026-08-06 2026 8 2026-08-06 2026-11-24 2026-11-25 04:59:59 0 2026-10-04 09:00:15   1 0 09000064b940e756
FDA-2026-N-9505-0002 FDA FDA-2026-N-9505 Robotically-Assisted Surgical Devices - Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Draft Guidance Other Guidance 2026-09-25 2026 9 2026-09-25 2026-11-24 2026-11-25 04:59:59 0 2026-10-07 09:00:30   1 0 09000064b95c6e19
FDA-2026-N-10100-0001 FDA FDA-2026-N-10100 FDA Scientific Public Workshop: Next-Generation Sequencing for Adventitious Agent Detection in Biologics Notice Meeting 2026-08-31 2026 8 2026-09-23 2026-11-22 2026-11-23 04:59:59 0 2026-08-31 22:10:19   1 0 09000064b94b538f
FDA-2026-N-10363-0001 FDA FDA-2026-N-10363 Agency Information Collection Activities; Proposed Collection; Comment Request; Temporary Marketing Permit Applications Notice 60 Day Proposed Information Collection 2026-09-21 2026 9 2026-09-21 2026-11-20 2026-11-21 04:59:59 0 2026-09-21 17:16:01 2026-19283 1 0 09000064b959db67
FDA-2026-N-10430-0001 FDA FDA-2026-N-10430 Agency Information Collection Activities; Proposed Collection; Comment Request; State Petitions for Exemption From Preemption Notice 60 Day Proposed Information Collection 2026-09-21 2026 9 2026-09-21 2026-11-20 2026-11-21 04:59:59 0 2026-09-21 17:21:17 2026-19282 1 0 09000064b959db5f
FDA-2026-N-10033-0001 FDA FDA-2026-N-10033 Agency Information Collection Activities; Proposed Collection; Comment Request; Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 Notice 60 Day Proposed Information Collection 2026-09-21 2026 9 2026-09-21 2026-11-20 2026-11-21 04:59:59 0 2026-09-22 09:00:47 2026-19281 1 0 09000064b959dbae
FDA-2026-N-10429-0001 FDA FDA-2026-N-10429 Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information Notice Requests for Information (RFI) 2026-10-06 2026 10 2026-10-06 2026-11-20 2026-11-21 04:59:59 0 2026-10-08 09:00:49 2026-20427 1 0 09000064b962e7b9
FDA-2026-D-8561-0001 FDA FDA-2026-D-8561 Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry; Availability Notice Notice of Availability 2026-08-20 2026 8 2026-08-20 2026-11-18 2026-11-19 04:59:59 0 2026-08-20 17:54:40 2026-16960 1 0 09000064b946c7f3
FDA-2026-D-8561-0002 FDA FDA-2026-D-8561 Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry Other Guidance 2026-08-20 2026 8 2026-08-20 2026-11-18 2026-11-19 04:59:59 0 2026-08-20 17:59:44   1 0 09000064b946ee4d
FDA-2026-D-9429-0001 FDA FDA-2026-D-9429 Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff; Availability Notice Notice of Availability 2026-09-18 2026 9 2026-09-18 2026-11-17 2026-11-18 04:59:59 0 2026-09-18 18:00:19 2026-19181 1 0 09000064b958f5ee
FDA-2026-D-9429-0002 FDA FDA-2026-D-9429 Electronic Submission Template for Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff - Draft Guidance Other Guidance 2026-09-18 2026 9 2026-09-18 2026-11-17 2026-11-18 04:59:59 0 2026-09-18 18:06:45   1 0 09000064b95876d8
FDA-2026-D-7233-0001 FDA FDA-2026-D-7233 Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products; Draft Guidance for Industry; Availability Notice Notice of Availability 2026-09-18 2026 9 2026-09-18 2026-11-17 2026-11-18 04:59:59 0 2026-09-18 18:09:09 2026-19141 1 0 09000064b958f536
FDA-2025-N-2787-0007 FDA FDA-2025-N-2787 Biosimilar User Fee Act III Future Needs in the Development of Interchangeable Products Post-Workshop; Draft Strategy Document Notice Notice of Availability 2026-09-18 2026 9 2026-09-18 2026-11-17 2026-11-18 04:59:59 0 2026-09-18 18:37:52 2026-19166 1 0 09000064b958ecea
FDA-2025-N-2787-0008 FDA FDA-2025-N-2787 BsUFA III Future Needs for the Development of Interchangeable Products; Post-Workshop Strategy Document Other Request 2026-09-18 2026 9 2026-09-18 2026-11-17 2026-11-18 04:59:59 0 2026-09-25 09:00:32   1 0 09000064b9592e12
FDA-2026-D-7233-0002 FDA FDA-2026-D-7233 Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products VICH GL62; Guidance for Industry (GFI) #298 - Draft Guidance Other Guidance 2026-09-18 2026 9 2026-09-18 2026-11-17 2026-11-18 04:59:59 0 2026-09-25 09:00:32   1 0 09000064b958e85f
FDA-2026-N-10165-0001 FDA FDA-2026-N-10165 Statistical Considerations for the Design of Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Comments Notice Request for Comments 2026-09-15 2026 9 2026-09-15 2026-11-13 2026-11-14 04:59:59 0 2026-09-16 09:00:44 2026-18805 1 0 09000064b955afbc
FDA-2026-N-8692-0001 FDA FDA-2026-N-8692 Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Pathogen-Agnostic Sequencing Notice Request for Comments 2026-09-16 2026 9 2026-09-16 2026-11-12 2026-11-13 04:59:59 0 2026-10-04 09:00:20 2026-18920 1 0 09000064b956b6a9
FDA-2026-N-9350-0001 FDA FDA-2026-N-9350 Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Tracking Notice 60 Day Proposed Information Collection 2026-09-11 2026 9 2026-09-11 2026-11-10 2026-11-11 04:59:59 0 2026-09-30 09:00:20 2026-18529 1 0 09000064b951dd42
FDA-2024-E-4125-0005 FDA FDA-2024-E-4125 Determination of Regulatory Review Period for Purposes of Patent Extension; ANKTIVA Notice Determinations 2026-09-09 2026 9 2026-09-09 2026-11-09 2026-11-10 04:59:59 0 2026-09-09 17:47:05 2026-18297 1 0 09000064b9506ef3
FDA-2024-E-4128-0005 FDA FDA-2024-E-4128 Determination of Regulatory Review Period for Purposes of Patent Extension; ANKTIVA Notice Determinations 2026-09-09 2026 9 2026-09-09 2026-11-09 2026-11-10 04:59:59 0 2026-09-09 17:49:59 2026-18297 1 0 09000064b94cc9f8
FDA-2024-E-4129-0005 FDA FDA-2024-E-4129 Determination of Regulatory Review Period for Purposes of Patent Extension; ANKTIVA Notice Determinations 2026-09-09 2026 9 2026-09-09 2026-11-09 2026-11-10 04:59:59 0 2026-09-09 17:52:57 2026-18297 1 0 09000064b94cc9f9
FDA-2024-E-4130-0005 FDA FDA-2024-E-4130 Determination of Regulatory Review Period for Purposes of Patent Extension; ANKTIVA Notice Determinations 2026-09-09 2026 9 2026-09-09 2026-11-09 2026-11-10 04:59:59 0 2026-09-09 17:56:33 2026-18297 1 0 09000064b94cc9fa
FDA-2024-E-4131-0005 FDA FDA-2024-E-4131 Determination of Regulatory Review Period for Purposes of Patent Extension; ANKTIVA Notice Determinations 2026-09-09 2026 9 2026-09-09 2026-11-09 2026-11-10 04:59:59 0 2026-09-09 18:01:24 2026-18297 1 0 09000064b94cc9fb
FDA-2025-E-3595-0005 FDA FDA-2025-E-3595 Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEMBRY Notice Determinations 2026-09-09 2026 9 2026-09-09 2026-11-09 2026-11-10 04:59:59 0 2026-09-09 18:09:30 2026-18300 1 0 09000064b9506ef2
FDA-2025-E-3596-0005 FDA FDA-2025-E-3596 Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEMBRY Notice Determinations 2026-09-09 2026 9 2026-09-09 2026-11-09 2026-11-10 04:59:59 0 2026-09-09 18:12:58 2026-18300 1 0 09000064b94cc9fc
FDA-2025-E-3939-0005 FDA FDA-2025-E-3939 Determination of Regulatory Review Period for Purposes of Patent Extension; ANZUPGO Notice Determinations 2026-09-09 2026 9 2026-09-09 2026-11-09 2026-11-10 04:59:59 0 2026-09-09 18:26:41 2026-18298 1 0 09000064b9506dda
FDA-2026-N-9638-0001 FDA FDA-2026-N-9638 Agency Information Collection Activities; Proposed Collection; Comment Request; Human Cells, Tissues, and Cellular and Tissue-Based Products Notice 60 Day Proposed Information Collection 2026-09-09 2026 9 2026-09-09 2026-11-09 2026-11-10 04:59:59 0 2026-09-29 09:00:25 2026-18333 1 0 09000064b9506ea0
FDA-2026-N-8361-0001 FDA FDA-2026-N-8361 Agency Information Collection Activities; Proposed Collection; Comment Request; Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers To Advance Pregnancy Safety Data Collection and Improve Health Communications Notice 60 Day Proposed Information Collection 2026-09-09 2026 9 2026-09-09 2026-11-09 2026-11-10 04:59:59 0 2026-10-03 09:00:40 2026-18299 1 0 09000064b9506ef8
FDA-2026-N-10738-0001 FDA FDA-2026-N-10738 Improving Patient Access to Deceased Donor Islet Cells and Cell Products; Request for Information Notice Requests for Information (RFI) 2026-09-24 2026 9 2026-09-24 2026-11-09 2026-11-10 04:59:59 0 2026-10-08 09:00:48 2026-19563 1 0 09000064b95b6b07
FDA-2026-N-7605-0001 FDA FDA-2026-N-7605 Establishment of a Quantitative Medicine Innovation Network: Scope, Feasibility, and Opportunities; Request for Information Notice Requests for Information (RFI) 2026-08-05 2026 8 2026-08-05 2026-11-03 2026-11-04 04:59:59 0 2026-10-03 09:00:26 2026-15887 1 0 09000064b93ff4d4
FDA-2026-N-9550-0001 FDA FDA-2026-N-9550 Advancing Development of Botanical Drug Products; Request for Information Notice Requests for Information (RFI) 2026-09-04 2026 9 2026-09-04 2026-11-03 2026-11-04 04:59:59 0 2026-10-08 09:00:45 2026-18133 1 0 09000064b94cc083
FDA-2026-N-7914-0001 FDA FDA-2026-N-7914 Public Meeting on Listeria monocytogenes Prevention Other Additional Information 2026-08-03 2026 8 2026-08-03 2026-11-02 2026-11-03 04:59:59 0 2026-08-19 09:01:12   1 0 09000064b93e5b66
FDA-2026-N-6876-0005 FDA FDA-2026-N-6876 Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program Notice 30 Day Proposed Information Collection 2026-10-01 2026 10 2026-10-01 2026-11-02 2026-11-03 04:59:59 0 2026-10-01 17:10:26 2026-20085 1 0 09000064b95fa835
FDA-2026-N-8690-0001 FDA FDA-2026-N-8690 Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated Fees Notice 60 Day Proposed Information Collection 2026-08-31 2026 8 2026-08-31 2026-10-30 2026-10-31 03:59:59 0 2026-08-31 17:28:32 2026-17676 1 0 09000064b94afcfe
FDA-2026-N-9349-0001 FDA FDA-2026-N-9349 Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Reports of Removals and Corrections Notice 60 Day Proposed Information Collection 2026-08-31 2026 8 2026-08-31 2026-10-30 2026-10-31 03:59:59 0 2026-08-31 17:33:15 2026-17675 1 0 09000064b94afbd8
FDA-2026-N-2743-0003 FDA FDA-2026-N-2743 Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503 Notice 30 Day Proposed Information Collection 2026-09-29 2026 9 2026-09-29 2026-10-29 2026-10-30 03:59:59 0 2026-09-29 17:13:03 2026-19850 1 0 09000064b95e920c
FDA-2026-N-10606-0001 FDA FDA-2026-N-10606 Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01% Notice Request for Comments 2026-09-25 2026 9 2026-09-25 2026-10-29 2026-10-30 03:59:59 0 2026-10-08 09:00:48 2026-19700 1 0 09000064b95c540b
FDA-2026-N-8691-0001 FDA FDA-2026-N-8691 Agency Information Collection Activities; Proposed Collection; Comment Request; Food Canning Establishment Registration, Process Filing, and Recordkeeping for Acidified Foods and Thermally Processed Low-Acid Foods in Hermetically Sealed Containers Notice 60 Day Proposed Information Collection 2026-08-28 2026 8 2026-08-28 2026-10-27 2026-10-28 03:59:59 0 2026-08-28 17:30:23 2026-17599 1 0 09000064b94a6404
FDA-2026-N-8087-0001 FDA FDA-2026-N-8087 Agency Information Collection Activities; Proposed Collection; Comment Request; Focus Groups and Interviews as Used by the Food and Drug Administration Notice 60 Day Proposed Information Collection 2026-08-28 2026 8 2026-08-28 2026-10-27 2026-10-28 03:59:59 0 2026-08-28 17:52:27 2026-17598 1 0 09000064b949f63c
FDA-2026-N-8898-0001 FDA FDA-2026-N-8898 Agency Information Collection Activities; Proposed Collection; Comment Request; Qualitative Feedback on Agency Service Delivery Notice 60 Day Proposed Information Collection 2026-08-28 2026 8 2026-08-28 2026-10-27 2026-10-28 03:59:59 0 2026-09-06 09:00:29 2026-17605 1 0 09000064b94a6385
FDA-2026-N-8482-0001 FDA FDA-2026-N-8482 Agency Information Collection Activities; Proposed Collection; Comment Request; Allegations of Regulatory Misconduct Voluntarily Submitted to the Center for Devices and Radiological Health Notice Request for Comments 2026-08-26 2026 8 2026-08-26 2026-10-26 2026-10-27 03:59:59 0 2026-08-27 09:00:24 2026-17377 1 0 09000064b94982b2
FDA-2026-N-5057-0001 FDA FDA-2026-N-5057 Patient-Focused Drug Development for Nonhealing Chronic Wounds; Public Meeting; Request for Comments Notice Request for Comments 2026-05-29 2026 5 2026-05-29 2026-10-26 2026-10-27 03:59:59 0 2026-09-30 09:00:14 2026-10752 1 0 09000064b92fcf66
FDA-2021-F-1157-0003 FDA FDA-2021-F-1157 Food Additives Permitted for Direct Addition to Food for Human Consumption; Vitamin D2 Inactive Bakers Yeast Rule Final Rule 2026-09-25 2026 9 2026-09-25 2026-10-26 2026-10-27 03:59:59 0 2026-10-05 09:00:31 2026-19656 1 0 09000064b95c657c
FDA-2007-D-0369-2652 FDA FDA-2007-D-0369 PSG_020816 - Draft Guidance on Brinzolamide Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:08:40   1 0 09000064b9470607
FDA-2007-D-0369-2653 FDA FDA-2007-D-0369 PSG_020732 - Draft Guidance on Buprenorphine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:08:45   1 0 09000064b94706ae
FDA-2007-D-0369-2654 FDA FDA-2007-D-0369 PSG_204370 - Draft Guidance on Cariprazine Hydrochloride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:08:55   1 0 09000064b94706b0
FDA-2007-D-0369-2655 FDA FDA-2007-D-0369 PSG_050600 - Draft Guidance on Clindamycin Phosphate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:04   1 0 09000064b94706b2
FDA-2007-D-0369-2656 FDA FDA-2007-D-0369 PSG_215425 - Draft Guidance on Epinephrine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:08   1 0 09000064b94706b4
FDA-2007-D-0369-2657 FDA FDA-2007-D-0369 PSG_218475 - Draft Guidance on Epinephrine Bitartrate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:13   1 0 09000064b94706b6
FDA-2007-D-0369-2658 FDA FDA-2007-D-0369 PSG_203565 - Draft Guidance on Ferric Carboxymaltose Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:18   1 0 09000064b94706b8
FDA-2007-D-0369-2659 FDA FDA-2007-D-0369 PSG_022180 - Draft Guidance on Ferumoxytol Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:23   1 0 09000064b94706ba
FDA-2007-D-0369-2660 FDA FDA-2007-D-0369 PSG_020243 - Draft Guidance on Fluvoxamine Maleate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:28   1 0 09000064b94706bc
FDA-2007-D-0369-2661 FDA FDA-2007-D-0369 PSG_020496 - Draft Guidance on Glimepiride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:33   1 0 09000064b94706be
FDA-2007-D-0369-2662 FDA FDA-2007-D-0369 PSG_213876 - Draft Guidance on Hydrocortisone Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:38   1 0 09000064b94706c0
FDA-2007-D-0369-2663 FDA FDA-2007-D-0369 PSG_206185 - Draft Guidance on Latanoprost Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:42   1 0 09000064b94706c2
FDA-2007-D-0369-2664 FDA FDA-2007-D-0369 PSG_209939 - Draft Guidance on Letermovir Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:09   1 0 09000064b94706c4
FDA-2007-D-0369-2665 FDA FDA-2007-D-0369 PSG_021343 - Draft Guidance on Leuprolide Acetate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:14   1 0 09000064b94706c6
FDA-2007-D-0369-2666 FDA FDA-2007-D-0369 PSG_021379 - Draft Guidance on Leuprolide Acetate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:19   1 0 09000064b94706c8
FDA-2007-D-0369-2667 FDA FDA-2007-D-0369 PSG_021731 - Draft Guidance on Leuprolide Acetate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:24   1 0 09000064b94706ca
FDA-2007-D-0369-2668 FDA FDA-2007-D-0369 PSG_021924 - Draft Guidance on Levothyroxine Sodium Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:29   1 0 09000064b94706cc
FDA-2007-D-0369-2669 FDA FDA-2007-D-0369 PSG_215029 - Draft Guidance on Lidocaine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:35   1 0 09000064b94706ce
FDA-2007-D-0369-2670 FDA FDA-2007-D-0369 PSG_021977 - Draft Guidance on Lisdexamfetamine Dimesylate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:41   1 0 09000064b94706d0
FDA-2007-D-0369-2671 FDA FDA-2007-D-0369 PSG_219847 - Draft Guidance on Lisdexamfetamine Dimesylate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:46   1 0 09000064b94706d2
FDA-2007-D-0369-2672 FDA FDA-2007-D-0369 PSG_219485 - Draft Guidance on Maralixibat Chloride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:51   1 0 09000064b94706d4
FDA-2007-D-0369-2673 FDA FDA-2007-D-0369 PSG_214662 - Draft Guidance on Maralixibat Chloride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:06   1 0 09000064b94706d6
FDA-2007-D-0369-2674 FDA FDA-2007-D-0369 PSG_217593 - Draft Guidance on Meloxicam Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:11   1 0 09000064b94706d8
FDA-2007-D-0369-2675 FDA FDA-2007-D-0369 PSG_218395 - Draft Guidance on Meloxicam Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:15   1 0 09000064b94706da
FDA-2007-D-0369-2676 FDA FDA-2007-D-0369 PSG_215211 - Draft Guidance on Miglustat Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:20   1 0 09000064b94706dc
FDA-2007-D-0369-2677 FDA FDA-2007-D-0369 PSG_020415 - Draft Guidance on Mirtazapine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:25   1 0 09000064b94706de
FDA-2007-D-0369-2678 FDA FDA-2007-D-0369 PSG_215793 - Draft Guidance on Mitomycin Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:30   1 0 09000064b94706e0
FDA-2007-D-0369-2679 FDA FDA-2007-D-0369 PSG_203340 - Draft Guidance on Nimodipine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:34   1 0 09000064b94706e2
FDA-2007-D-0369-2680 FDA FDA-2007-D-0369 PSG_021008 - Draft Guidance on Octreotide Acetate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:40   1 0 09000064b9470826
FDA-2007-D-0369-2681 FDA FDA-2007-D-0369 PSG_208558 - Draft Guidance on Olaparib Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:45   1 0 09000064b9470828
FDA-2007-D-0369-2683 FDA FDA-2007-D-0369 PSG_020781 - Draft Guidance on Ondansetron Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:55   1 0 09000064b947082c
FDA-2007-D-0369-2684 FDA FDA-2007-D-0369 PSG_211150 - Draft Guidance on Pitolisant Hydrochloride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:15   1 0 09000064b947082e
FDA-2007-D-0369-2685 FDA FDA-2007-D-0369 PSG_219685 - Draft Guidance on Rilzabrutinib Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:21   1 0 09000064b9470830
FDA-2007-D-0369-2686 FDA FDA-2007-D-0369 PSG_219301 - Draft Guidance on Sebetralstat Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:25   1 0 09000064b9470832
FDA-2007-D-0369-2687 FDA FDA-2007-D-0369 PSG_020573 - Draft Guidance on Sodium Phenylbutyrate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:30   1 0 09000064b9470834
FDA-2007-D-0369-2688 FDA FDA-2007-D-0369 PSG_214860 - Draft Guidance on Sodium Phenylbutyrate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:41   1 0 09000064b9470836
FDA-2007-D-0369-2689 FDA FDA-2007-D-0369 PSG_219839 - Draft Guidance on Sunvozertinib Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:46   1 0 09000064b9470838

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
            id TEXT PRIMARY KEY,
            agency_id TEXT,
            docket_id TEXT,
            title TEXT,
            document_type TEXT,
            subtype TEXT,
            posted_date TEXT,
            posted_year INTEGER,
            posted_month INTEGER,
            comment_start_date TEXT,
            comment_end_date TEXT,      -- EASTERN calendar date of the close (queue #498 writer
                                        -- fix, 2026-09-05; was the UTC-rolled day AFTER the ET
                                        -- deadline before that). Display-grade only.
            comment_end_datetime TEXT,  -- full UTC close ("YYYY-MM-DD HH:MM:SS", queue #498):
                                        -- the API expresses the 11:59:59 PM ET deadline as a UTC
                                        -- datetime. AUTHORITATIVE: the predicate, days_left and
                                        -- any timezone-aware render derive from THIS column.
            perpetual_docket INTEGER,   -- 1 = sentinel end date (queue #464); NULL = no end date
            last_modified TEXT,
            fr_doc_num TEXT,
            open_for_comment INTEGER,
            withdrawn INTEGER,
            object_id TEXT
        );
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date);
CREATE INDEX idx_docs_withdrawn ON documents(withdrawn);
CREATE INDEX idx_docs_perpetual ON documents(perpetual_docket);
Powered by Datasette · Queries took 2.306ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API · Privacy